| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124038 | European Journal of Cancer | 2010 | 6 Pages |
Abstract
Oral perifosine was tolerable up to 600Â mg/week in cancer patients when administered with meal and prophylactic antiemetics. Based on its half-life of about 4Â days, a weekly regimen may be appropriate.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Clemens Unger, Wolfgang Berdel, Axel-R Hanauske, Herbert Sindermann, Jürgen Engel, Klaus Mross,